1. Home
  2. DSP vs OABI Comparison

DSP vs OABI Comparison

Compare DSP & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

N/A

Current Price

$13.62

Market Cap

279.6M

Sector

Technology

ML Signal

N/A

Logo OmniAb Inc.

OABI

OmniAb Inc.

N/A

Current Price

$4.32

Market Cap

294.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DSP
OABI
Founded
1999
2012
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
279.6M
294.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DSP
OABI
Price
$13.62
$4.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
2
Target Price
$17.81
$4.50
AVG Volume (30 Days)
283.3K
2.1M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
6.56
EPS
N/A
N/A
Revenue
$344,201,000.00
$18,666,000.00
Revenue This Year
$20.27
$52.42
Revenue Next Year
$16.88
$64.69
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$1.32
52 Week High
$14.80
$5.43

Technical Indicators

Market Signals
Indicator
DSP
OABI
Relative Strength Index (RSI) 57.35 69.68
Support Level $10.36 $1.71
Resistance Level $13.36 N/A
Average True Range (ATR) 0.57 0.37
MACD 0.03 0.01
Stochastic Oscillator 72.05 58.89

Price Performance

Historical Comparison
DSP
OABI

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: